Last reviewed · How we verify
neostigmine and glycopyrrolate or atropine
neostigmine and glycopyrrolate or atropine is a Cholinesterase inhibitor with anticholinergic agent Small molecule drug developed by Merck Sharp & Dohme LLC. It is currently in Phase 3 development for Reversal of neuromuscular blockade, Myasthenia gravis.
Neostigmine inhibits acetylcholinesterase to increase acetylcholine levels, while glycopyrrolate or atropine blocks muscarinic receptors to prevent cholinergic side effects.
Neostigmine inhibits acetylcholinesterase to increase acetylcholine levels, while glycopyrrolate or atropine blocks muscarinic receptors to prevent cholinergic side effects. Used for Reversal of neuromuscular blockade, Myasthenia gravis.
At a glance
| Generic name | neostigmine and glycopyrrolate or atropine |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | Cholinesterase inhibitor with anticholinergic agent |
| Target | Acetylcholinesterase (neostigmine); muscarinic acetylcholine receptors (glycopyrrolate/atropine) |
| Modality | Small molecule |
| Therapeutic area | Neuromuscular disorders |
| Phase | Phase 3 |
Mechanism of action
Neostigmine is a cholinesterase inhibitor that prevents the breakdown of acetylcholine, thereby enhancing neuromuscular transmission. The co-administered anticholinergic agent (glycopyrrolate or atropine) blocks muscarinic acetylcholine receptors to mitigate unwanted parasympathomimetic effects such as excessive salivation, bronchospasm, and bradycardia while preserving the beneficial nicotinic effects at the neuromuscular junction.
Approved indications
- Reversal of neuromuscular blockade
- Myasthenia gravis
Common side effects
- Bradycardia
- Increased salivation
- Bronchospasm
- Muscle fasciculations
- Nausea
Key clinical trials
- NMBA Reversal and Postoperative Urinary Retention
- Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616) for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to <2 Years (MK-8616-169) (PHASE4)
- Reversal of Neuromuscular Blockade With Sugammadex or Usual Care in Hip Fracture Surgery or Joint (Hip/Knee) Replacement (P07038) (PHASE3)
- Efficacy, Safety, and Pharmacokinetics of Sugammadex for Reversal of Neuromuscular Blockade (NMB) in Pediatric Participants (MK-8616-089) (PHASE4)
- Deep Neuromuscular Block for Laparoscopic Surgery (PHASE4)
- Intraoperative Lidocaine Infusion vs. Esmolol Infusion for Postoperative Analgesia in Laparoscopic Cholecystectomy (PHASE4)
- Segmental Epidural Anesthesia (SEA) V/S General Anesthesia for PCNL (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- neostigmine and glycopyrrolate or atropine CI brief — competitive landscape report
- neostigmine and glycopyrrolate or atropine updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI
Frequently asked questions about neostigmine and glycopyrrolate or atropine
What is neostigmine and glycopyrrolate or atropine?
How does neostigmine and glycopyrrolate or atropine work?
What is neostigmine and glycopyrrolate or atropine used for?
Who makes neostigmine and glycopyrrolate or atropine?
What drug class is neostigmine and glycopyrrolate or atropine in?
What development phase is neostigmine and glycopyrrolate or atropine in?
What are the side effects of neostigmine and glycopyrrolate or atropine?
What does neostigmine and glycopyrrolate or atropine target?
Related
- Drug class: All Cholinesterase inhibitor with anticholinergic agent drugs
- Target: All drugs targeting Acetylcholinesterase (neostigmine); muscarinic acetylcholine receptors (glycopyrrolate/atropine)
- Manufacturer: Merck Sharp & Dohme LLC — full pipeline
- Therapeutic area: All drugs in Neuromuscular disorders
- Indication: Drugs for Reversal of neuromuscular blockade
- Indication: Drugs for Myasthenia gravis
- Compare: neostigmine and glycopyrrolate or atropine vs similar drugs
- Pricing: neostigmine and glycopyrrolate or atropine cost, discount & access